معرفی
Professor Iain MacPherson is a distinguished Professor of Breast Oncology at the University of Glasgow's Institute of Cancer Sciences, based at the Wolfson Wohl Cancer Research Centre. His research focuses on Rab-coupling protein (RCP)-mediated receptor trafficking in breast cancer progression, with particular emphasis on understanding mechanisms of metastasis and therapeutic resistance.
- Specializes in breast cancer molecular biology and clinical translation
- Leads multiple clinical trials in breast cancer therapeutics
- Active member of the Glasgow Experimental Cancer Medicine Centre (ECMC)
- Collaborates extensively with national and international cancer research groups
MacPherson's research program centers on cancer cell invasion mechanisms with particular focus on receptor trafficking pathways that drive breast cancer progression and resistance to therapy. His work spans from basic molecular investigations into integrin and growth factor receptor trafficking to clinical applications in breast cancer treatment. Recent studies have examined ESR1 mutations in hormone resistance, cardiovascular complications of breast cancer therapies, and innovative approaches to detect molecular residual disease using circulating tumor DNA. His laboratory has made significant contributions to understanding how Rab GTPases and CLIC proteins regulate receptor recycling pathways that influence cancer cell behavior.
Analysis of his recent publications reveals strong emphasis on translating molecular discoveries into clinical applications, particularly in the areas of therapeutic resistance mechanisms, cardiovascular monitoring during breast cancer treatment, and development of novel biomarker strategies. His work frequently appears in high-impact journals including Science Advances, Nature Communications, and Lancet Oncology, demonstrating both scientific rigor and clinical relevance.
MacPherson has received substantial research funding from major organizations including Cancer Research UK, National Institute for Health Research, and Chief Scientist Office. His current grants include the CESAR study (2024-2027), HER2 platform study (2021-2029), and multiple projects investigating the gut microbiome's role in chemotherapy response.
As a clinical researcher, MacPherson has contributed significantly to trials examining neoadjuvant therapy, targeted treatments, and strategies to mitigate treatment side effects. His work on the Cardiac CARE trial represents an important contribution to cardio-oncology, addressing a critical issue in long-term breast cancer survivorship.
His laboratory at the Wolfson Wohl Cancer Research Centre maintains active collaborations with multiple research groups across the UK and internationally, focusing on translating molecular discoveries into clinical applications for breast cancer patients.
